Premium
TMD chronic pain and masseter silent period in psychiatric patients on antidepressive therapy
Author(s) -
IVKOVIC N.,
MLADENOVIC I.,
PETKOVIC S.,
STOJIC D.
Publication year - 2008
Publication title -
journal of oral rehabilitation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.991
H-Index - 93
eISSN - 1365-2842
pISSN - 0305-182X
DOI - 10.1111/j.1365-2842.2007.01819.x
Subject(s) - medicine , maprotiline , masseter muscle , antidepressant , diazepam , psychiatry , depression (economics) , physical therapy , anxiety , dentistry , macroeconomics , economics
Summary The aim of the study was to evaluate the long‐term effects of antidepressive therapy on chronic pain and related disability, and masseter silent period in psychiatric depressive patients with temporomandibular disorders (TMD). The study included hospitalized psychiatric depressive patients on antidepressive therapy protocol (tetracyclic antidepressant‐maprotiline and anxiolytic‐diazepam) ( n = 30) and non‐psychiatric patients seeking prosthodontic treatment (control group, n = 38). TMD were diagnosed by Research Diagnostic Criteria for temporomandibular disorders proposed by Dworkin and LeResche. The surface electromyography was recorded from left and right masseter muscles and masseter inhibitory reflex (masseter silent period) was recorded after mechanical stimulation. The incidence of TMD appearance was very similar, of aproximately 40% in both group of patients. The results of the study also indicated a higher prevalence of joint related TMD, a lower prevalence of muscular subtype of TMD and a lower grade of chronic pain and related disability in the psychiatric group of patients on antidepressive therapy in comparison with findings in the control group. In the patients on antidepressive therapy with TMD masseter silent period was not prolonged, while in the control group of patients with TMD the prolongation of the silent period was observed. The study provided evidence that long‐term, combined therapy (maprotiline and diazepam) in psychiatric depressive patients significantly modulated signs and symptoms of TMD in comparison with the control group.